ClinicalTrials.gg
CompletedNCT01271387Updated Feb 17, 2014

Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment

A Phase 1 interventional study of tasimelteon in Hepatic Impairment, sponsored by Vanda Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-17.

Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 368 studies in Liver Diseases with a site in United States — 45 open to participants now, 59 under way, 5 of them phase 3. Liver Diseases · United States.

Enrollment
169th of 269
29 · median 48
Started
2011
with 15 others
Phase 1
62 of 368
4 open now
Registered
97th of 368
by date

Among the 368 studies in Liver Diseases with a site in United States, this one is the 169th largest by enrollment of the 269 interventional ones that give a count, is one of 16 that started in 2011, is one of 62 in phase 1, and was the 97th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

45 of the 368 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 368 studies in Liver Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon (including its breakdown products) in the blood in individuals with mild or moderate liver disease compared to individuals who have normal liver function.

Read the detailed description

The study will employ an open-label, parallel-group design. Up to 32 subjects will be enrolled in 3 groups: Group 1 will consist of 8 subjects with mild hepatic impairment; Group 2 will consist of 8 subjects with moderate hepatic impairment; Group 3 will consist of up to 16 healthy subjects matched by gender, age, smoking status, and body mass index, to Groups 1 and/or 2. For each group, there will be a 21-day screening period, a baseline period, a single-dose treatment period with an on-site observation period of 36 hours, and a study completion evaluation conducted after the last PK blood sample is drawn. Each subject will receive a single 20-mg dose of tasimelteon, after which safety assessments will be performed.

03

Conditions studied

  • Hepatic Impairment

Browse trials for

Keywords

  • Liver disease
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Subjects:

  • Ability and acceptance to provide written ;
  • Men or women between 18 - 75 years, inclusive;
  • Subjects with (BMI) of >18 and \<35 kg/m2;
  • Women of must be using an acceptable method of ;
  • Willing and able to comply with study requirements and restrictions;

Subjects with mild or moderate hepatic impairment:

  • Stable hepatic impairment satisfying the criteria for Class A or B of the modified classification documented by medical history;
  • Subjects with Moderate hepatic impairment must also have either liver cirrhosis or physical signs consistent with a clinical diagnosis of liver cirrhosis
  • greater than 50 mL/min

Healthy matched controls:

  • Matched to subjects with hepatic impairment by gender, age, BMI, and smoking status
  • Good health as determined by past medical history, physical examination, , laboratory tests, vital signs and urinalysis;

Exclusion criteria

Exclusion Criteria:

  • Smokers unable or unwilling to limit consumption;
  • Exposure to any drug, including placebo, within 30 days of dosing;
  • Blood Donation or loss of 400 mL or more within two months prior to dosing;
  • Significant illness within the two weeks prior to dosing;
  • History of autonomic dysfunction;
  • History of acute or chronic bronchospastic disease, including asthma and , treated or not treated;
  • A known to tasimelteon or drugs similar to tasimelteon including melatonin;
  • Pregnant or lactating females;
  • History of drug or alcohol abuse within the 12 months prior to screening
  • History of immunocompromise, including a positive (ELISA and Western blot) test result;
  • Any surgical or medical condition which might significantly alter the absorption, distribution or excretion of any drug;
  • abnormalities or vital sign abnormalities at screening or a history of unstable, severe, or clinically significant cardiovascular disease;

Subjects with mild or moderate hepatic impairment:

  • Clinically significant abnormal findings, not consistent with clinical disease, upon physical examination, ECG, or laboratory evaluation;
  • Current symptoms or past history (within the last 6 months) of encephalopathy;
  • Severe ascites;
  • Previous surgical porto-systemic shunt including transjugular intrahepatic portosystemic shunt (TIPS);
  • Progressive liver disease within 4 weeks prior to screening.

Healthy matched controls:

  • Use of any prescription medication within 1 month of dosing, and OTC medication within 14 days prior to dosing;
  • History or presence of liver disease or liver injury;
  • A positive surface antigen (HBsAg) or test result.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Moderate Hepatic Impairment

    Drug: tasimelteon

  • Experimental
    Mild Hepatic Impairment

    Drug: tasimelteon

  • Experimental
    Healthy Volunteers

    Drug: tasimelteon

Interventions

  • 20 mg tasimelteon capsules, PO single dose

    Also known as: VEC-162, BMS-214778

06

What researchers measure

Primary outcomes

  1. Plasma concentrations and PK of tasimelteon

    To assess plasma concentrations and pharmacokinetics of tasimelteon in subjects with mild or moderate hepatic impairment compared to healthy subjects with normal hepatic function.

    Time frame: 36 hours

Secondary outcomes

  1. Plasma concentrations and PK of tasimelteon metabolites

    To assess plasma concentrations and pharmacokinetics of tasimelteon metabolites in subjects with mild or moderate hepatic impairment compared to healthy subjects with normal hepatic function.

    Time frame: 36 hours

  2. Safety

    To assess the safety and tolerability of a single 20-mg oral dose of tasimelteon.

    Time frame: 36 hours

07

Study locations

1 site
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2011
First posted
Jan 6, 2011
Start
Jan 2011
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Last update
Feb 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01271387
Responsible party
Sponsor
First posted
Jan 6, 2011
Start date
Jan 2011
Primary completion
Aug 2011
Completion
Aug 2011
Last update
Feb 17, 2014

Study contacts

Vanda Pharmaceuticals
study director · Vanda Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion